相关实验视频
Updated: Jan 17, 2026

08:12
Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans
Published on: October 5, 2020
3.4K
鉴定KRAS突变 (G12C,G12D和G12V) 抑制剂的发现
Vikas Yadav1, Mohammad Kashif1,2, Zenab Kamalia3
1School of Computational and Integrative Sciences, Jawaharlal Nehru University, New Delhi, India.
Future medicinal chemistry
|September 17, 2025
概括
研究人员确定了针对KRAS G12V和G12C突变的新型小分子抑制剂. 这些化合物显示出有前途的抗癌活性,特别是针对KRAS驱动的瘤,支持进一步的治疗开发.
科学领域:
- 在瘤学瘤学.
- 药用化学 医学化学
- 计算生物学 计算生物学
背景情况:
- 包括G12C,G12D和G12V在内的KRAS突变在各种癌症中普遍存在,推动瘤生长和进展.
- 针对这些特定的KRAS突变,为开发新型癌症疗法带来了重大挑战和机会.
- 现有的疗法往往缺乏特异性,导致异于目标效果,在某些患者群体中有效性有限.
研究的目的:
- 发现和验证新的小分子抑制剂,专门针对KRAS G12C,G12D和G12V突变.
- 采用基于结构的药物设计方法,与实验验证相结合.
- 识别具有显著抗癌活性的潜在候选药物,对抗KRAS突变癌症.
主要方法:
- 利用分子对接,分子动力学 (MD) 模拟和MM-PBSA计算来虚拟选潜在的抑制剂.
- 采用主要组件分析 (PCA) 来分析模拟数据并确定关键绑定相互作用.
- 使用生物层干扰测量 (BLI) 测定结合亲和力和MTT测定乳腺癌和肺癌细胞系中的抗癌活性,实验验证的顶级化合物.
主要成果:
- 化合物C797-1505表现出强大的结合KRAS G12V (KD = 141μM),超过了参考药物索托拉西布 (KD = 345μM).
- 化合物C190-0346对KRAS G12C表现出较弱的亲和力.
- MTT测定显示C797-1505降低了乳腺癌细胞活力 (IC50 = 43.51 μM),两种化合物都对肺癌细胞表现出显著的细胞毒性 (IC50 = 18.78 μM 和 22.93 μM).
结论:
- 综合计算和实验策略成功识别了KRAS突变的选择性抑制剂.
- 已识别的化合物,特别是C797-1505,对KRAS G12V和G12C驱动的瘤表现出有希望的抗癌活性.
- 这些发现保证了这些新型抑制剂作为向癌症治疗的进一步临床前开发.
关键词:
克拉斯 (Kras) 是一个国家.在MAPK路径中.在NSCLCLC中,我们可以看到NSCLCLC.我们的PDAC是PDAC.结肠癌是什么意思结肠癌是什么意思分子动力学模拟,分子动力学模拟原则组件分析和自由能源景观.基于结构的药物设计.更多相关视频
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
18.6K
12:40A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
15.2K
相关概念视频
The Ras Gene
7.1K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
7.1K
Small GTPases - Ras and Rho
5.2K
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Three regulatory proteins control their activity:
5.2K
Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
In-vitro Mutagenesis
16.0K
To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.
16.0K